Specific JAK inhibitors, such as Filgotinib, Upadacitinib, and PF04965842, or TYK2 inhibitors and BMS-986165, are currently in clinical development for autoimmune diseases rheumatoid arthritis (RA), psoriasis, and Crohn’s disease [127]. Here, TYK2 is linked to rheumatoid arthritis.